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Abstract
Background: Cardioplegia is used for protection of myocardium during cardiac operations. Del Nido® (DN) and Custodiol® car-
dioplegia (CC) solutions are used for prolonged protection of the myocardium during cardiopulmonary bypass (CPB). Custodiol®
cardioplegia solution is gaining popularity for myocardial protection during cardiopulmonary bypass.
Objectives: This study aimed to compare the effects of Custodiol® with another cardioplegia solution, Del Nido®, on myocardial
protection during cardiopulmonary bypass.
Methods: In a randomized controlled clinical trial, forty patients were randomly allocated to Del Nido® and Custodiol® (CC) groups.
Patients in both groups received a standard anesthesia protocol. For cardioplegia, in the DN group, the Del Nido® solution was
administered every 90 minutes by the antegrade route. In the CC, group, the Custodiol® solution was administered in the same way
at the beginning of the cardioplegia. Demographic information, blood chemistry parameters and other related perioperative and
postoperative clinical indices were recorded.
Results: Frequency of female patients was 14/21 (66.66%) in the DN and 12/19 (63.15%) in the CC group (P = 0.816), age was 57.14± 12.48
years versus 59.47± 11.96 years (P = 0.551), weight was 70.95±9.56 kilograms versus 69.63± 7.64 kilograms (P = 0.635), CPB time was
103.19± 23.43 minutes versus 97.36± 16.7 minutes (P = 0.376), and cross-clamp time was 73.76± 19.66 minutes versus 83.95± 16.14
minutes (P = 0.083). Blood chemistry and blood gas analysis revealed a similar trend between the two groups in these parameters (P
> 0.05) except for higher sodium levels after cardioplegia (P = 0.016) and end of CPB (P = 0.002), potassium levels after cardioplegia
(P = 0.029), and bicarbonate anions at the end of bypass (P = 0.03) in the Custodiol® group.
Conclusions: In conclusion, CC and DN offer effective myocardial protection during cardiopulmonary bypass. It is recommended
to restrict the use of CC in patients susceptible to electrolyte disturbances.
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1. Background
Cardiovascular diseases are amongst the most im-
portant causes of mortality and morbidity worldwide.
Atherosclerosis, lifestyle, and congenital disorders may
cause cardiovascular diseases, which are complex in na-
ture (1-4). These complications require surgical treatment.
In complex cardiac disorders, duration of the operation
is more than normal and prolonged protection of the
myocardial tissue against the post-cardiopulmonary by-
pass (CPB) ischemia/reperfusion injury (IRI) is required
(1). Cardioplegia provides a still and blood-free work field
for the surgeon (5). Inactivity of the muscles along with
hypothermia during cardioplegia causes decline in cell’s
metabolic demand. Although cellular inactivity decreases
the metabolic demand and reduces ischemic damage,
basal metabolism is active inside the cells and causes cells
to enter anaerobic metabolism in the absence of oxygen.
The anaerobic metabolism and collection of its byprod-
ucts causes elevation of free radicals in the tissue (5). Af-
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ter blood flow reestablishment after clamp removal, reper-
fusion injury starts with the recruitment of the immune
cells to the ischemic tissue. The inflammatory response, in-
cluding cellular immune response and inflammatory me-
diators, damages the cardiomyocytes and may impair its
function. Furthermore, IRI causes a series of events in the
affected tissue, which results in cell death and impaired
organ function (6-9). Furthermore, the systemic inflam-
matory response is induced in response to this local IR in-
jury. The release of cytokines and other inflammatory me-
diators may result in critical organ damage in sites dis-
tant to the myocardium (10). To prevent this cascade of
adverse events, management of myocardial ischemia and
reperfusion injury is very important to 1, prevent damage
to myocardium itself and 2, to stall systemic inflammatory
response and distant critical organ damage. Many meth-
ods, including premedication and post-medication strate-
gies, ultrafiltration, and cytokine filters have been stud-
ied in the management of the inflammatory response and
reperfusion injury (5-9, 11-13). However, cardioplegia solu-
tions as the first agent achieving the cardiomyocytes, ex-
actly upon ischemia, are of profound importance. Vari-
ous formulations of cardioplegia solutions have been de-
veloped to go further beyond just stopping the heartbeat
and offer superior protection against ischemia by multi-
tude of actions like free radical scavenging activity, block-
ing the calcium influx and diastolic stiffness, and resisting
pH changes through high buffering capacity (1, 10, 14-16).
Classical cardioplegia solutions are administered in
a multi-dose manner, which requires renewing the car-
dioplegia shots in definite intervals. Cardiac surgeons are
interested in single-dose cardioplegia solutions because of
their durable tissue protection during cardiopulmonary
bypass (CPB). Two cardioplegia solutions are introduced
for more durable myocardial protection during complex
procedures: histidine-tryptophan-ketoglutarate (HTK),
Bretschneider’s, or Custodiol® (CC), and Del Nido® (DN)
cardioplegia solution. Durable protection by these car-
dioplegia solutions enables uninterrupted performance
of complex procedures (15-21). Due to low sodium and
calcium content of the CC, sodium depletion of the ex-
tracellular space occurs after hyperpolarization of the
myocyte plasma membrane by administration of this
solution and results in diastolic cardiac arrest (5, 21, 22).
Like CC, DN solution is also intended for one-shot admin-
istration. Formulation, properties, and methods of use
of Custodiol® and DN solutions have been described else-
where (10, 23). However, their cardioprotective properties
has not been compared in the context of complex cardiac
operations, including coronary artery bypass grafting
(CABG), aortic valve replacement (AVR), and mitral valve
replacement (MVR). The current study aimed at compar-
ing the cardioprotective properties and perioperative
and post-surgical clinical and biochemical outcomes be-
tween patients receiving DN and Custodiol® cardioplegia
solutions.
2. Methods
2.1. Study Design
A randomized, double-blinded, no use of placebo,
single-center controlled clinical trial study was performed
to compare the effects of two cardioplegia solutions, DN
and Custodiol®, on perioperative outcomes, including the
following criteria duration of operation, duration of CPB
and pump-time, blood chemistry parameters, blood and
blood products transfusion, intensive care unit (ICU) stay
duration, use of defibrillator, hemodynamics, cardiac mus-
cle damage, and blood gas analysis. All ethical concerns
regarding medical research, including human subjects,
according to the Helsinki declaration was followed. The
study protocol was confirmed by the research ethics com-
mittee of Tehran University of the Medical Sciences (TUMS)
(registration code: IR.TUMS.MEDICINE.REC.1396.3509). All
patients gave their informed consent for participation in
the study. Study protocol was registered at the Iranian reg-
istry of clinical trials (http://irct.ir/) with registration num-
ber IRCT2016042627617N1. Blinding was done on patients
and outcome assessors (nurses registering the clinical out-
comes and laboratory personnel measuring the biochem-
ical parameters). Patients were unaware of the type of
cardioplegia solution. The anesthesiologist and the anes-
thesia team performed the allocation of the patients to
two groups and administered the cardioplegia solution.
Since both cardioplegia solutions were single-dose, sur-
geons and other surgery team members were also unaware
of the allocation sequence. Also ICU nurses and laboratory
technicians were blind to the patients and their samples
being analyzed in the laboratory. Patients were included
in the study, if they were a candidate for at least two of
the conditions of coronary artery bypass grafting, mitral
valve graft surgery, and aortic valve graft surgery. Patients
were excluded if they were diagnosed with inflammatory
diseases before surgery, acute myocardial infarction, and
patient dissatisfaction in any part of the study, dialysis-
requiring renal failure, ejection fraction less than 15%, sec-
ond surgery, emergency patients, predictive pulmonary
disease patients, and cardiomyopathy patients. Since there
was no estimate of differences in parameters between the
groups of patients treated with these two cardioplegia so-
lutions, the researchers used convenience sampling and
conducted this pilot study to find an estimate of the differ-
ences between two cardioplegia solutions. The researchers
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set a target sample size for this study as 40 patients. Data
extraction center was a central state-owned independently
operating specialty hospital in cardiac care. Patients were
randomly allocated to two groups as described earlier. One
group received DN and the other received Custodiol® car-
dioplegia (CC) solution.
2.2. Anesthesia Induction and Cardioplegia
Anesthesia induction was performed with the same
procedure and similar medications for all patients. Pa-
tients were then ventilated with an anesthesia machine
with a respiratory flow volume of 10 mL/kg of body weight
adjusted to respiratory rate, according to the age and
maintenance of CO2 pressure (PaCO2) between 30 and 35
mmHg. Cardioplegia solutions were administered with a
standard procedure in an antegrade manner as previously
described for DN (10, 23) and CC (24) solutions. Briefly, DN
was administered in the antegrade delivery through aor-
tic root as a single-shot (20 mL/kg; 1000 mL maximum)
and further doses delivered after 90 minutes if required.
Custodiol® cardioplegia was administered in antegrade
manner as a single dose of 25 mL/kg over five to seven min-
utes. Further doses were administered after three hours.
2.3. Data Collection
Patients’ demographic information including age,
weight, height, body surface area (BSA), and gender were
recorded. Cardiac troponin I were measured in all patients
before anesthesia induction, after CPB and 24 hours af-
ter ICU. Other parameters of cross-clamp time, CPB time,
mechanical ventilation, hemodynamic parameters, blood
chemistry, transfusion of blood and blood products, and
the use of inotropes were recorded according to the medi-
cal records of the hospital. Laboratory measurements were
performed by the clinical diagnostic laboratory of the hos-
pital as part of a routine practice of in vitro diagnostics in
the center. The devices were checked and calibrated as a
part of everyday practice in the diagnostics laboratory of
the center. Laboratory staff were unaware of the groups to
which every patient was assigned.
2.4. Statistical Analysis
Data were analyzed using IBM SPSS Statistics for Win-
dows, Version 20 (IBM Corp., Armork, N,Y., USA). Data for
continuous variables were presented as mean± standard
deviation (SD) if they followed normal distribution. In
case of violation from normal distribution, data were pre-
sented as median (interquartile range, IQR). Categorical
data were presented as relative frequency and frequency
percentage. Mixed analysis of variance (ANOVA) was used
for analysis of changes in measurements of continuous
Table 1. Demographic Information of the Patients Receiving Two Cardioplegia Solu-
tions Del Nido® and Custodiol® a
Variables Del Nido® Custodiol® P Value
Age, y 57.14± 12.48 59.47± 11.96 0.551
Weight, kg 70.95± 9.56 69.63± 7.64 0.635
Body surface area,m2 1.79± 0.14 1.75± 0.12 0.291
Frequency, referent: female,
Frequency (%)
14/21 (66.66) 12/19 (63.15) 0.816
aContinuous data are presented as mean± standard deviation (SD). Patients’
gender distribution of each group is presented as relative frequency and fre-
quency percent of female patients to male and female patients in each group.
variables over time wherever required. To control the post-
intervention measures of variables for differences in pre-
intervention measures, these values were set as covariates
in mixed ANOVA models. Mann-Whitney U test was used
for comparison of continuous variables between groups if
the data distribution violated the normal distribution as-
sumption. Chi-square test was used for comparison of the
frequency of categorical variables between the two groups.
The level of significance and power of the analysis were set
to 0.05 and 0.8, respectively.
3. Results
Seventy-one patients were initially screened according
to the inclusion and exclusion criteria. Thirty-one were not
included because twenty-two did not meet the inclusion
criteria and nine patients refused to participate. Forty pa-
tients were included in the current study, 21 of which re-
ceived DN and 19 underwent deep cardioplegia with CC. All
patients finished the study, and their data were included
in the analysis (Figure 1). Mean age of the subjects in two
groups was 57.14± 12.48 and 59.47± 11.96 years in DN and
CC groups, respectively (P = 0.551). No significant differ-
ence was observed between the subjects of the two groups
in terms of their demographic variables (P > 0.05; Table 1).
Also, the kind of operations between the two groups were
similar (P = 0.594; Table 3).
Table 2. Type of Operations in the Two Groups of Patients Receiving Different Kinds
of Cardioplegia Solutions
Del Nido® Group Custodiol®
Group
P Value
CABG.AVR 3 3
0.594MVR.AVR 7 9
MVR.CABG 11 7
Abbreviations: CABG.AVR, Coronary Artery Bypass Grafting and Aortic Valve Re-
placement; MVR.AVR, Mitral Valve Replacement and Aortic Valve Replacement;
MVR.CABG, Mitral Valve Replacement and Coronary Artery Bypass Grafting.
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Enrollment 
Assessed for eligibility (n = 71) 
Excluded (n = 31) 
•   Not meeting inclusion criteria (n = 22) 
•   Declined to participate (n = 9) 
•   Other reasons (n = 0) 
Randomized (n = 40) 
Allocated to Custodiol (n = 19) 
• Received allocated intervention (n = 19) 
• Did not receive allocated intervention (give 
reasons) (n = 0) 
Lost to follow-up (give reasons) (n = 0) 
Discontinued intervention (give reasons) (n = 0) 
Analyzed (n =19) 
• Excluded from analysis (give reasons) (n = 0) 
Allocated to Del Nido (n = 21) 
• Received allocated intervention (n = 21) 
• Did not receive allocated intervention (give 
reasons) (n = 0) 
Lost to follow-up (give reasons) (n = 0) 
Discontinued intervention (give reasons) (n = 0) 
Analyzed (n = 21) 
• Excluded from analysis (give reasons) (n = 0) 
Allocation 
Follow-Up 
Analysis
Figure 1. CONSORT flow diagram of the study
The findings of the study on the relationship between
kind of cardioplegia solution and the perioperative out-
comes demonstrated no significant differences between
the two groups in case of CPB time, cross-clamp duration,
urine output, chest tube drainage, duration of mechanical
ventilation, and ICU stay (P > 0.05; Table 3).
No significant differences were observed in mean arte-
rial pressure (MAP) and ejection fraction (EF) between the
two groups (Table 3).
Blood chemistry parameters and blood gas analysis re-
vealed a similar trend between the two groups in these pa-
rameters (P > 0.05) except for sodium levels after cardio-
plegia (P = 0.016) and end of CPB (P = 0.002), potassium lev-
els after cardioplegia (P = 0.029), and bicarbonate anions at
the end of bypass (P = 0.03). These amounts were lower in
the CC group as compared with the DN group (Table 4). Two
groups were also identical in the use of blood products,
such as pack cell, platelet, fresh-frozen plasma, and plasma
cryoprecipitate. Also, use of dopamine, epinephrine, nore-
pinephrine, and Milrinone during operation and in the
ICU was similar between the two groups (Table 5).
4. Discussion
In the current trial, the researchers demonstrated that
Custodiol® and DN cardioplegia solutions had similar car-
dioprotective properties. Patients undergoing cardiople-
gia using one of these solutions demonstrated similar out-
comes in terms of perioperative and postoperative param-
eters. They did not show any significant differences in
CPB time, cross-clamp duration, urine output, chest tube
drainage, and duration of mechanical ventilation.
The convenience offered by single dose cardioplegia so-
lutions encouraged the development of various cardiople-
gia solutions for the myocardial protection during CPB. Be-
cause they enabled durable cardioplegia without the need
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Table 3. Perioperative Parameters, Hemodynamics and Blood Chemistry Parameters of Two Groups of Patients Receiving Two Cardioplegia Solutions Del Nido® and
Custodiol® a
Varietals Del Nido® Custodiol® P Value
CPB time,min 103.19± 23.42 97.36± 16.7 0.376
Cross clamp time,min 73.76± 19.66 83.95± 16.14 0.083
Urine output during operation,mL 507.14± 215.22 555.26± 228.46 0.497
Chest tube drainage after operation,mL 319.0± 125.65 316.11± 102.73 0.939
Duration ofmechanical ventilation, h 10.91± 4.0 10.79± 3.59 0.934
ICU stay, days 2.22± 0.45 2.53± 0.68 0.101
MAP before bypass,mmHg 75.95± 11.83 70.94± 5.73 0.109
MAP bypass beginning,mmHg 64.81± 6.16 67.9± 6.72 0.138
MAP post-bypass,mmHg 65.96± 15.11 71.26.9.63 0.199
MAP ICU entrance,mmHg 72.5± 10.09 72.75± 8.7 0.937
MAP 24 hours post-ICU,mmHg 72.1± 9.64 76.06± 12.04 0.267
MAP 48 hours post-ICU,mmHg 66.33± 8.6 67.63± 7.34 0.612
EF before surgery, % 42.14± 8.79 43.84± 8.12 0.531
EF post-bypass, % 40.52± 7.17 42.32± 7.75 0.452
EF on discharge, % 41.67± 12.32 41.79± 7.15 0.97
BUN pre-operation,mg/dL 23.38± 16.24 19.32± 5.94 0.31
BUN post-operation,mg/dL 21.33± 12.12 23.26± 11.03 0.603
BUN 24 hours post-operation,mg/dL 22.19± 7.14 22.26± 6.6 0.974
Cr pre-operation,mg/dL 0.9± 0.21 0.92± 0.21 0.713
Cr post-operation,mg/dL 0.86± 0.3 1.03± 0.28 0.07
Cr 24 hours post-operation,mg/dL 0.86± 0.3 1.03± 0.28 0.982
CK pre-operation, U/L 13.76± 6.33 5.74± 9.93 0.464
CK 24 hours post-operation, U/L 65.72± 31.38 54.66± 29.16 0.255
CTnI pre-operation, ng/mL 0.59± 2.61 0.49± 2.06 0.893
CTnI 24 hours post-operation, ng/mL 3.71± 2.39 3.06± 2.75 0.431
Abbreviations: BUN, blood urea nitrogen; CK, creatine kinase; CPB, cardiopulmonary bypass; Cr, creatinine; cTnI, cardiac troponin I; EF, ejection fraction, ICU, intensive
care unit; MAP, mean arterial pressure.
aValues are expressed as mean± standard deviation (SD).
to stop the flow of surgical operation, one of the advan-
tages of the use of single-dose cardioplegia solutions was
the decrease of cross-clamp time. Since both cardioplegia
solutions used in the current study were cardioplegia so-
lutions for single-dose administration, similar cross-clamp
time between the two groups appeared sensible. The de-
crease in the cross-clamp time is usually associated with
other outcomes, such as CPB time, mechanical ventilation
duration, and intensive care unit stay (23, 25), although
further evidence supports the notion that even multi-dose
cardioplegia does not influence the CPB time and cross-
clamp duration (1, 17). It is no surprise that these items
are also similar in the groups of patients receiving two
different single-doses of cardioplegia solution. Also, no
differences in hemodynamic parameters, including mean
arterial pressure and EF, were observed between the two
groups, which is consistent with the data available from
other studies (1, 10).
Blood chemistry parameters were similar between the
two groups. Exceptions were sodium ions after cardiople-
gia and after bypass, potassium ions after cardioplegia and
bicarbonate ions, which were significantly lower in the CC
group compared to the DN group. Hyponatremia is re-
ported as a common outcome when using intracellular
cardioplegic solutions (17, 26, 27). The same was observed
in the current study. Moreover, potassium level in patients
in the CC group was slightly lower, which makes sense as
Custodiol® cardioplegia solution is a non-potassium based
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Table 4. Blood Gas Analysis of the Two Groups of Patients Receiving Two Cardioplegia Solutions Del Nido® and Custodiol® a , b
Variables Del Nido® Custadiol P Value
Na pre-CPB,mEq/L 142.8± 4.59 142.52± 6.22 0.87
Na early CPB,mEq/L 134.91± 3.25 132.37± 3.1 0.016
Na end CPB,mEq/L 133.86± 3.58 129.58± 4.43 0.002
Na ICU entrance,mEq/L 139.76± 4.25 137.26± 5.27 0.106
Na 6 hours post-ICU,mEq/L 140.67± 4.16 139.52± 4.72 0.422
K pre-CPB,mEq/L 3.54± 0.47 3.63± 0.66 0.602
K early CPB,mEq/L 4.72± 0.74 4.25± 0.54 0.029
K end CPB,mEq/L 4.6± 0.8 4.33± 0.56 0.238
K ICU entrance,mEq/L 4.14± 0.62 4.05± 0.61 0.623
K 6 hours post-ICU,mEq/L 4.48± 0.5 4.37± 0.44 0.456
BS pre-CPB,mg/dL 95.52± 29.73 94.84± 24.63 0.938
BS early CPB,mg/dL 130.95± 35.37 126.16± 30.05 0.649
BS end CPB,mg/dL 161.91± 46.09 146.42± 33.08 0.234
BS ICU entrance,mg/dL 176.95± 60.74 168.39± 56.55 0.657
BS 6 hours post-ICU,mg/dL 163.05± 56.18 154.24± 49.4 0.622
Hgb pre-CPB, g/dL 12.58± 1.32 12.75± 1.12 0.672
Hgb early CPB, g/dL 8.63± 1.54 7.95± 1.09 0.115
Hgb end CPB, g/dL 8.9± 1.21 8.46± 1.08 0.248
Hgb ICU entrance, g/dL 10.34± 1.0 10.23± 1.28 0.755
Hgb 6 hours post-ICU, g/dL 10.41± 1.15 10.0± 1.33 0.313
pHpre-CPB 7.47± 0.07 7.43± 0.07 0.132
pH early CPB 7.38± 0.08 7.37± 0.08 0.652
pH end CPB 7.41± 0.04 7.39± 0.05 0.106
HCO3 pre-CPB,mEq/L 20.95± 2.59 22.21± 2.64 0.137
HCO3 early CPB,mEq/L 20.0± 2.1 19.37± 1.77 0.313
HCO3 end, CPBmEq/L 21.24± 2.17 19.95± 1.39 0.03
Abbreviations: BS, blood sugar; K, blood potassium.
aNa, blood sodium.
bValues are expressed as mean± standard deviation (SD).
cardioplegic solution and lacks potassium ions (22, 26).
Another significant outcome was lower bicarbonate
ions at the end of CPB in the CC group compared with the
DN group. This decrease in blood ions may also be due to
excess fluid infusion in the CC group compared with the
DN group, which may have caused the decline in the blood
plasma electrolytes. Although bicarbonate level was lower
in the blood of the CC group, the amount of this metabo-
lite was in the normal range in most of the patients in both
groups and was not associated with considerable blood pH
deviations from the normal range. These are consistent
with previous findings (14, 22, 26).
Cardiac troponin I (cTnI) levels were elevated in 24
hours post-operation. However, the amount of this marker
was not significantly different between the two groups as
measured in before and 24 hours post-operation. The cTnI
is a marker of cardiac muscle damage, which is elevated in
response to the death of cardiac myocytes and the release
of its contents to the circulation (1, 5, 14, 17, 22, 27). The sim-
ilarity of the cTnI levels between the two groups demon-
strated that two cardioplegia solutions offered similar pro-
tection against the acute damage of the cardiomyocytes.
The two groups had a similar profile regarding the use
of inotropes, blood cells, transfusion of blood products,
hemoglobin, and hematocrit levels. This indicates that
these cardioplegia solutions affect the parameters in the
same way. Other studies have demonstrated that these
parameters are not significantly affected by single dose
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Table 5. Blood Products Transfusion of Two Groups of Patients Receiving Two Car-
dioplegia Solutions Del Nido® and Custodiol® a
Variables Del Nido® Custodiol® P Value
PC OR 23.8 15.8 0.408
PC ICU 38.1 42.1 0.525
PLT OR 4.8 15.8 0.265
PLT ICU 4.8 0.0 0.525
FFP OR 4.8 15.8 0.265
FFP ICU 4.8 15.8 0.265
CRYOOR 0.0 5.3 0.475
CRYO ICU 0.0 0.0 1.0
DOPAMINOR 0.0 5.3 0.475
DOPAMIN ICU 0.0 5.3 0.475
EPI OR 28.6 42.1 0.51
EPI ICU 28.6 26.3 0.578
NOREPI OR 0.0 5.3 0.475
NOREPI ICU 4.8 0.0 0.525
Milrinone OR 19 10.5 0.381
Milrinone ICU 19 21.1 1.0
Abbreviations: CRYO, plasma cryoprecipitate, EPI, epinephrine; FFP, fresh
frozen plasma; ICU, intensive care unit; NOREPI, norepinephrine, OR, operat-
ing room; PC, pack cell, PLT, platelet.
aData are presented as relative frequency percent of the patients receiving the
specific item of the blood and blood components during operation or in the
intensive care unit (ICU) to all patients in that group.
cardioplegia solutions in comparison with conventional
multi-dose cardioplegia solutions (1, 10, 14, 20). Therefore,
it appears that this finding can also be justified by the re-
sults of previous studies.
In summary, it appears that the cardioprotective prop-
erties of the DN and Custodiol® cardioplegia solutions dur-
ing CPB are comparable. Therefore, the choice of one of
these single-dose cardioplegia solutions is very dependent
on its availability, pricing, and the choice of the surgeon,
perfusionist and the anesthesia team. However, a major
concern exists over its use in patients susceptible to se-
vere electrolyte disturbances. Since electrolytes imbalance
raise due to various reasons, such as hormonal imbalance,
renal dysfunction or use of specific medications (e.g. di-
uretics) (28, 29) may cause serious damage to multiple or-
gans including the brain, kidneys, and other critical or-
gans (30, 31), special care should be taken in case of patients
susceptible to electrolytes imbalance. It is recommended
to restrict the use of Custodiol® in these patients to pre-
vent the adverse outcomes linked to electrolyte imbalance
during and after CPB.
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